Revenue
2019
2020
2021
2022
2023
2024
2025
2026
BIOTRICITY INC. (BTCY)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2022
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 · Dec 31 | 2015 · Aug 31 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $13.8M | $12.1M | $9.6M | $7.7M | $3.4M | $1.4M | $398,200 | — | — | — | — | — | — |
| Gross profit | $12.9M | $10.6M | $8.4M | $5.4M | $4.6M | $1.3M | $485,774 | $59,865 | — | — | — | — | — | — |
| Research & development | $2.8M | $2.2M | $2.6M | $3.2M | $2.7M | $2.1M | $1.4M | $1.3M | $1.8M | $1.1M | $1.1M | $1.1M | $23,200 | — |
| Operating expenses | $11.3M | $13.0M | $17.2M | $20.9M | $21.3M | $14.6M | $11.4M | $8.7M | $7.7M | $5.9M | $5.0M | $5.1M | — | — |
| Operating income | $1.7M | −$2.4M | −$8.8M | −$15.4M | −$16.7M | — | — | — | — | — | — | — | — | — |
| Net income | −$2.4M | −$8.4M | −$14.1M | −$18.7M | −$29.1M | −$15.5M | −$11.1M | −$8.6M | −$8.6M | −$7.8M | −$7.3M | −$5.2M | −$90,813 | −$91,072 |
| Basic EPSper diluted share | -$0.12 | -$0.56 | -$1.66 | -$2.26 | -$0.67 | -$0.44 | -$0.32 | -$0.26 | -$0.29 | -$0.30 | -$0.29 | -$0.24 | -$0.02 | -$0.02 |
| Diluted EPSper diluted share | -$0.12 | -$0.56 | -$1.66 | -$2.26 | — | -$0.44 | -$0.32 | -$0.26 | -$0.29 | -$0.30 | -$0.29 | -$0.24 | -$0.02 | -$0.02 |